Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

BioLineRx (BLRX) has made regulatory submissions to the Finnish National Supervisory Authority for Welfare and Health (Valvira) for initiating a phase I/II study on the company’s candidate BL-7010. The candidate is being developed for the treatment of celiac disease.

BioLineRx expects to initiate the two-part (single and repeated), double-blind, placebo-controlled, dose escalation study by year end. The company intends to enrol 32 patients for the study. The study will primarily evaluate the safety of single and repeated ascending doses of BL-7010. Results should be out in mid-2014. BioLineRx mentioned in its press release that the celiac market is expected to reach $8 billion by 2019.

BioLineRx has progressed well on its pipeline in recent times. Earlier this month, the company’s pipeline candidate BL-8040 was granted orphan drug designation by the U.S. Food & Drug Administration (FDA) in the acute myeloid leukemia (AML) indication.

BioLineRx’ BL-8040 is currently in a phase II study for the treatment of AML. BioLineRx is also evaluating BL-8040 for the treatment of thrombocytopenia (reduced platelet production). Last month the company reported positive results from pre-clinical trials on the candidate, where it was proved to be effective for the treatment of thrombocytopenia.

Apart from BL-7010 and BL-8040, BioLineRx also has BL-5010 (skin lesions), BL-7040 (inflammatory bowel disease) and BL-1021 (neuropathic pain) in its pipeline.

BioLineRx presently carries a Zacks Rank #3 (Hold). Meanwhile, other companies like Actelion Ltd. (ALIOF), Anthera Pharmaceuticals, Inc. (ANTH - Snapshot Report) and Athersys, Inc. (ATHX - Snapshot Report) look better positioned. While Actelion carries a Zacks Rank #1 (Strong Buy), Anthera and Athersys carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%